Deal facts
- Buyer
- Pelthos Therapeutics Inc.
- Target
- Castle Creek Biosciences, Inc.
- Deal value
- Not disclosed
- Announced
- 30 October 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares, earn-out
Sources
Pelthos Therapeutics Inc. signed an Agreement and Plan of Merger on October 30, 2026 to acquire Castle Creek Biosciences, Inc., according to Pelthos's Form 8-K of that date. The parties to the agreement are Pelthos, two Pelthos merger subsidiaries, Castle Creek, and Paragon Biosciences, LLC as securityholder representative. The structure is two sequential mergers: a merger subsidiary merges into Castle Creek, and Castle Creek then merges into a second merger subsidiary, which continues as a wholly owned Pelthos subsidiary. Pelthos issued a press release the same day announcing the agreement.
Castle Creek stockholders will receive their allocable share of 5,200,000 newly issued Pelthos common shares, with 10% of those shares held in escrow to back indemnification obligations and scheduled for release on the fifth business day after the second anniversary of closing, subject to pending claims. On that basis, Castle Creek holders are expected to own about 32.5% and existing Pelthos holders about 67.5% of Pelthos on a fully diluted basis, before the PIPE financing and excluding contingent shares.
Contingent consideration is tied to the D-Fi program. It includes five milestone payments of $50.0 million, $50.0 million, $50.0 million, $75.0 million and $75.0 million, linked to a specified clinical milestone achieved by June 30, 2029, first U.S. commercial sale and three trailing-twelve-month net sales thresholds of $100.0 million, $250.0 million and $500.0 million, subject to certain contingent expense adjustments. It also includes 5,800,000 contingent Pelthos shares if FDA approval of D-Fi comes by March 31, 2036, reduced by 5% for each full calendar quarter after March 31, 2031, plus 80% of net proceeds from the sale of any FDA priority review voucher granted in connection with approval of D-Fi. Castle Creek stockholders holding about 55.9% of its common stock signed support agreements, and holders of about 56.2% of Pelthos voting power, including Ligand, delivered written consent approving the share issuances.
A concurrent PIPE financing covers 57,500 shares of Series B Convertible Preferred Stock at a $1,000 stated value, plus warrants over 496,951 common shares, for roughly $57.5 million. Its maximum size including bridge financing is $80.0 million, and proceeds are intended to repay certain Castle Creek indebtedness and fund working capital. Closing requires an effective Form S-4, 20 calendar days after mailing of the information statement, expiry of the HSR waiting period, NYSE American listing approval of the new shares, and completion of the PIPE. Either side may terminate if the first merger has not closed by February 1, 2027, automatically extendable to March 31, 2027 in certain circumstances. The Pelthos board will grow from eight to ten directors, with two designated by Castle Creek.
The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.
Deal timeline
1 update- Firm intention
Pelthos Therapeutics Inc. firm intention to acquire Castle Creek Biosciences, Inc.
Item 1.01. Entry into a Material Definitive Agreement. Merger Agreement On October 30, 2026, Pelthos Therapeutics Inc., a Nevada corporation (“ Pelthos ” or “ Public Company ”), Credit Card Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Pelthos (“ Merger Sub ”), Credit Card Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Pelthos (“ M
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Drugs Made In America Acquisition II Corp. to acquire Alpha AI Biotech Group
Drugs Made in America Acquisition II Corp., a Cayman Islands special purpose acquisition company listed on Nasdaq, disclosed in a Form 8-K signed November 18, 2026 that…
- Buyer
- Drugs Made In America Acquisition II Corp.
- Target
- Alpha AI Biotech Group
- Deal value
- USD 600,000,000
- Deal type
- strategic acquisition
Aimei Health Technology Co., Ltd to acquire Hera Health Solutions Inc.
Aimei Health Technology Co., Ltd (Nasdaq: AFJK), a Cayman Islands blank check company, entered into a non-binding letter of intent on November 14, 2026 for a business co…
- Buyer
- Aimei Health Technology Co., Ltd
- Target
- Hera Health Solutions Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Wolfram Resources Plc to acquire Ellipses Pharma Limited
Wolfram Resources Plc (LSE: WFR), a Main Market listed special purpose acquisition company, confirmed on 16 November 2026 that it was in active discussions about a poten…
- Buyer
- Wolfram Resources Plc
- Target
- Ellipses Pharma Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MaxCyte, Inc. to acquire Akron BioProducts LLC
MaxCyte, Inc., the Nasdaq-listed cell-engineering company, has agreed to acquire Akron BioProducts LLC from affiliates of Arcline Investment Management. The Securities P…
- Buyer
- MaxCyte, Inc.
- Target
- Akron BioProducts LLC
- Deal value
- USD 151,800,000
- Deal type
- strategic acquisition
Buyer history
Pelthos Therapeutics Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive